Company Focus
UCB
Latest UCB News
Pharmaceutical
Belgian pharma UCB today announced that the Phase III study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and key secondary endpoints. 27 June 2025
Related News
Insights
Company Spotlight
A clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease.
Latest News & Features of interest to UCB
Biotechnology
US pharma major AbbVie is to buy Capstan Therapeutics, a San Diego-based biotech advancing in vivo engineering of cells through RNA delivery using tLNPs, for up to $2.1 billion in cash. 30 June 2025
Pharmaceutical
US biopharma Alto Neuroscience, a firm focused on the development of novel precision medicines for neuropsychiatric disorders, has highlighted The Lancet Psychiatry’s publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). 30 June 2025
Biotechnology
North Carolina, USA-based biotech BioCryst Pharmaceuticals on Friday announced it has signed a definitive agreement to sell its European Orladeyo (berotralstat) business to Italy’s Neopharmed Gentili for up to $264 million. 28 June 2025
article
Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi on Frida,y announced that the US Food and Drug Administration (FDA) approved Gamifant (emapalumab-lzsg) for a new indication, edging the company’s shares up 2.4% to 284.60 kronor. 28 June 2025
Biotechnology
Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell for investigational therapies aimed at interleukin-11 (IL-11), including a Phase I-stage monoclonal antibody targeting age-related conditions. 27 June 2025
Pharmaceutical
German drugmaker Bayer has renewed its partnership with China’s Tsinghua University for another three years, reinforcing its strategy to develop treatments aligned with China’s growing role in global biopharma R&D. 27 June 2025
Biotechnology
US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). 27 June 2025
Pharmaceutical
Belgian pharma UCB today announced that the Phase III study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and key secondary endpoints. 27 June 2025
Biotechnology
Australian biotech CSL Limited Europe-based subsidiary CSL Behring announced a milestone in the early benefit assessment of garadacimab by Germany’s Institute for Quality and Efficiency in Health Care (IQWiG). 26 June 2025
Biotechnology
Bayer’s cell therapy subsidiary BlueRock Therapeutics is shifting its priorities, cutting around 50 jobs and shutting its research labs in Massachusetts to streamline operations and concentrate on advanced-stage programs. 26 June 2025
Latest In Brief for UCB
Biotechnology
The benefits from Eli Lilly’s Kisluna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute for Health and Care Excellence (NICE), which also rejected Japanese drugmaker Eisai and US biotech Biogen Leqembi (lecanemab) for the same reason. 19 June 2025
Latest Relevant Ones To Watch News
US pharma major AbbVie is to buy Capstan Therapeutics, a San Diego-based biotech advancing in vivo engineering of cells through RNA delivery using tLNPs, for up to $2.1 billion in cash. 30 June 2025
16 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze